RE:RE:RE:RE:Interesting Oilminer. CGON was properly funded raising over $300 Million by venture capitalists lead by ORI Capital. This allowed them to remain privately held till they got the Fast Track and BTD at the same time. On the same they issued the IPO which was oversubscribed in Jan 2024. These are the list of Venture capitalist. We can claim that our Ruvidar is superior. But we have not been able to convince FDA till today.
My point is that Management makes a huge difference. Being in Nasdaq makes a difference. Being a US based company like CG Oncology has an Edge over a fairly unknown company in Canada. ORI Capital has a member on the Board of Director to oversee prudent management. This makes a difference. This is not a one man show lead by any Billionaire. This is a JV by several venture capitalist and resulted way better valuation than our TLT
ROI: CG had raised around $317 million in venture capital funding since its 2010 formation. Major backers included ORI Capital (11.3% pre-IPO stake), Decheng Capital (10.4%), Longitude Venture Partners (9.5%), Foresite Capital (6.3%), TCGX (6.3%), and Ally Bridge Group (5.7%).